Search research articles

Search research articles

Related Experiment Videos

5alpha-reductase activity in the prostate.

¹Department of Urology, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA

|December 26, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice.

Andrologia·2015

Same author

Encouraging scholastic publishing by urologic trainees.

Indian journal of urology : IJU : journal of the Urological Society of India·2009

Same author

Normal preoperative urodynamic testing does not predict voiding dysfunction after Burch colposuspension versus pubovaginal sling.

The Journal of urology·2008

Same author

Colpocleisis for pelvic organ prolapse: patient goals, quality of life, and satisfaction.

Obstetrics and gynecology·2007

Same author

Solifenacin significantly improves all symptoms of overactive bladder syndrome.

International journal of clinical practice·2006

Same author

Clinical ease of using doxazosin in BPH patients with and without hypertension.

Prostate cancer and prostatic diseases·2005

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Dihydrotestosterone (DHT), produced by 5alpha-reductase, drives prostate growth and benign prostatic hyperplasia (BPH). Inhibiting this enzyme reduces prostate size by inducing apoptosis and decreasing vascularization.

Area of Science:

Andrology
Urology
Biochemistry

Background:

Prostate development and growth are androgen-dependent.
Dihydrotestosterone (DHT) is the primary androgen responsible for prostate growth and benign prostatic hyperplasia (BPH) pathogenesis.
Testosterone is converted to DHT by 5alpha-reductase in prostatic cells.

Purpose of the Study:

To review the role of 5alpha-reductase in prostate physiology and BPH.
To discuss the mechanism of action of 5alpha-reductase inhibitors.
To highlight the different isozymes of 5alpha-reductase and their tissue distribution.

Main Methods:

Review of existing literature on 5alpha-reductase, DHT, and BPH.
Discussion of preclinical and clinical findings related to 5alpha-reductase inhibition.

Related Experiment Videos

Analysis of the expression patterns of 5alpha-reductase isozymes in various tissues.

Main Results:

5alpha-reductase inhibitors reduce prostate size by 20-30% through apoptosis and reduced vascularization.
Type-2 5alpha-reductase is predominant in the prostate, while type-1 is found in the liver and skin.
Genetic deficiencies in type-2 5alpha-reductase mimic BPH phenotypes observed in humans.
New dual inhibitors targeting both type-1 and type-2 5alpha-reductase are under clinical investigation.

Conclusions:

5alpha-reductase plays a critical role in prostate growth and BPH.
Inhibition of 5alpha-reductase is an effective therapeutic strategy for BPH.
Targeting both type-1 and type-2 isozymes may offer enhanced efficacy for BPH treatment.